NASDAQ:PRAH - PRA Health Sciences Stock Price, News, & Analysis

PRA Health Sciences trades on the NASDAQ under the ticker symbol "PRAH."

PRA Health Sciences Inc (NASDAQ:PRAH) announced its quarterly earnings results on Wednesday, October, 31st. The medical research company reported $1.13 EPS for the quarter, topping analysts' consensus estimates of $1.07 by $0.06. The medical research company earned $717.60 million during the quarter, compared to analyst estimates of $729.63 million. PRA Health Sciences had a return on equity of 26.55% and a net margin of 5.36%. The firm's revenue was up 23.3% on a year-over-year basis. During the same quarter last year, the firm posted $0.88 earnings per share. View PRA Health Sciences' Earnings History.

PRA Health Sciences is scheduled to release their next quarterly earnings announcement on Wednesday, April 24th 2019. View Earnings Estimates for PRA Health Sciences.

PRA Health Sciences issued an update on its FY19 earnings guidance on Wednesday, February, 27th. The company provided earnings per share guidance of $4.93-5.08 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.92. The company issued revenue guidance of $3.09-3.20 billion, compared to the consensus revenue estimate of $3.18 billion.PRA Health Sciences also updated its Q1 guidance to $1.05-1.10 EPS.

8 analysts have issued 1-year target prices for PRA Health Sciences' stock. Their forecasts range from $100.00 to $122.00. On average, they expect PRA Health Sciences' share price to reach $114.25 in the next twelve months. This suggests a possible upside of 4.4% from the stock's current price. View Analyst Price Targets for PRA Health Sciences.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PRA Health Sciences in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for PRA Health Sciences.

Press coverage about PRAH stock has trended negative this week, according to InfoTrie Sentiment. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. PRA Health Sciences earned a media sentiment score of -2.1 on InfoTrie's scale. They also gave media stories about the medical research company a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near future.

Some companies that are related to PRA Health Sciences include Incyte (INCY), EXACT Sciences (EXAS), Icon (ICLR), Exelixis (EXEL), Charles River Laboratories Intl. (CRL), Syneos Health (SYNH), BTG (BTGGF), Medpace (MEDP), Intrexon (XON), Eloxx Pharmaceuticals (ELOX), Sorrento Therapeutics (SRNE), STARPHARMA HOLD/S (SPHRY), Pieris Pharmaceuticals (PIRS), Anavex Life Sciences (AVXL) and Luna Innovations (LUNA).

Based on aggregate information from My MarketBeat watchlists, some companies that other PRA Health Sciences investors own include Alibaba Group (BABA), NVIDIA (NVDA), General Electric (GE), Twitter (TWTR), Mattel (MAT), Veeva Systems (VEEV), Ultra Clean (UCTT), Paypal (PYPL), Adobe (ADBE) and Chevron (CVX).

(PRAH) raised $306 million in an initial public offering (IPO) on Thursday, November 13th 2014. The company issued 17,000,000 shares at a price of $18.00 per share. Jefferies, Citigroup, KKR, UBS Investment Bank, Credit Suisse and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers.

PRA Health Sciences' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (9.48%), FMR LLC (3.98%), Bank of New York Mellon Corp (3.37%), Eagle Asset Management Inc. (1.64%), Pendal Group Ltd (1.36%) and Frontier Capital Management Co. LLC (1.34%). Company insiders that own PRA Health Sciences stock include Colin Shannon, David W Dockhorn, Linda Baddour, Matthew P Young and Pra Investors LP Kkr. View Institutional Ownership Trends for PRA Health Sciences.

PRAH stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Acadian Asset Management LLC, Swedbank, Bank of America Corp DE, Los Angeles Capital Management & Equity Research Inc., Vaughan Nelson Investment Management L.P., Gotham Asset Management LLC and Mitchell Capital Management Co.. View Insider Buying and Selling for PRA Health Sciences.

PRAH stock was bought by a variety of institutional investors in the last quarter, including Pendal Group Ltd, Standard Life Aberdeen plc, Norges Bank, Millennium Management LLC, Prudential Financial Inc., FMR LLC, First Trust Advisors LP and Frontier Capital Management Co. LLC. View Insider Buying and Selling for PRA Health Sciences.

Shares of PRAH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of PRAH stock can currently be purchased for approximately $109.44.

PRA Health Sciences has a market capitalization of $7.17 billion and generates $2.87 billion in revenue each year. The medical research company earns $153.90 million in net income (profit) each year or $3.93 on an earnings per share basis. PRA Health Sciences employs 16,400 workers across the globe.

The official website for PRA Health Sciences is http://www.prahs.com.

PRA Health Sciences' mailing address is 4130 PARKLAKE AVENUE SUITE 400, RALEIGH NC, 27612. The medical research company can be reached via phone at 919-786-8200 or via email at [email protected]